Biocryst Pharmaceuticals (BCRX) Return on Sales (2010 - 2026)

Biocryst Pharmaceuticals has reported Return on Sales for 17 years, with the latest figure at 0.05% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales fell 5.0% year-over-year to 0.05%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (down 1.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.05%, down from 3.47% in the prior quarter.
• The five-year high for Return on Sales was 3.47% in Q4 2025, with the low at 0.05% in Q1 2026.
• Historically, Return on Sales has averaged 0.2% across 5 years, with a median of 0.0% in 2023.
• Annual changes were most pronounced in 2025 — Return on Sales soared 347 bps — and 2026, when it slipped 5 bps.
• Biocryst Pharmaceuticals' Return on Sales stood at 0.01% in 2022, then climbed by 27 bps to 0.01% in 2023, then soared by 69 bps to 0.0% in 2024, then surged by 170556 bps to 3.47% in 2025, then tumbled by 101 bps to 0.05% in 2026.
• The last three Return on Sales figures came in at 0.05% (Q1 2026), 3.47% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.